AVITA Medical, Inc. (RCEL)
| Market Cap | 247.72M +93.5% |
| Revenue (ttm) | 75.63M +1.0% |
| Net Income | -43.08M |
| EPS | -1.44 |
| Shares Out | 30.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 404,030 |
| Open | 8.08 |
| Previous Close | 8.12 |
| Day's Range | 7.94 - 8.55 |
| 52-Week Range | 3.22 - 8.55 |
| Beta | 1.85 |
| Analysts | Strong Buy |
| Price Target | 9.02 (+12.61%) |
| Earnings Date | Aug 6, 2026 |
About RCEL
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting devi... [Read more]
Financial Performance
In 2025, AVITA Medical's revenue was $71.61 million, an increase of 11.45% compared to the previous year's $64.25 million. Losses were -$48.59 million, -21.44% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for RCEL stock is "Strong Buy." The 12-month stock price target is $9.02, which is an increase of 12.61% from the latest price.
News
AVITA Medical Transcript: Investor update
Revenue guidance raised to $86-$89 million for 2026, with cash flow breakeven expected in Q4. Strong sequential revenue growth, stable margins, and disciplined OpEx support this outlook. Nationwide CMS reimbursement changes and international expansion further strengthen growth prospects.
AVITA Medical Transcript: Canaccord Genuity's 46th Annual Growth Conference
Sequential revenue growth, raised guidance, and cost discipline position the business for cash flow breakeven by year-end. The three-product portfolio is gaining adoption, supported by strong clinical and economic data, with further growth expected as reimbursement simplifies in 2027.
AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif., Aug. 09, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholde...
Avita Medical price target raised to $8 from $6 at Lake Street
Lake Street analyst Frank Takkinen raised the firm’s price target on Avita Medical (RCEL) to $8 from $6 and keeps a Buy rating on the shares after what the firm…
AVITA Medical Announces Participation at Canaccord Genuity Growth Conference
VALENCIA, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced it...
Avita Medical upgraded to Buy from Neutral at BTIG
BTIG upgraded Avita Medical (RCEL) to Buy from Neutral with a $7 price target The firm, which believes that Q2 results reflect a business executing better than it did through…
Avita Medical reports Q2 EPS (25c), consensus (39c)
Reports Q2 revenue $21.7M, consensus $28.7M. The company said, “We delivered a strong second quarter, with revenue growing 18% year-over-year and 13% sequentially. As AVITA continues to expand utiliza...
AVITA Medical Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 18% year-over-year to $21.7 million, driven by strong adoption of RECELL and supporting products. Gross margin remained high at 81.9%, and guidance was raised to $86–$89 million for 2026, with cash flow breakeven expected in Q4.
AVITA Medical Earnings release: Q2 2026
AVITA Medical released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
AVITA Medical Quarterly report: Q2 2026
AVITA Medical has published its Q2 2026 quarterly earnings report on August 6, 2026.
AVITA Medical Slides: Q2 2026
AVITA Medical has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven
VALENCIA, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” ...
AVITA Medical to Announce Second Quarter 2026 Financial Results
VALENCIA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transfor...
Avita Medical price target raised to $12 from $5.50 at TD Cowen
TD Cowen analyst Joshua Jennings raised the firm’s price target on Avita Medical (RCEL) to $12 from $5.50 and keeps a Buy rating on the shares after having recently hosted…
Avita Medical announces presentation of new clinical data on use of RECELL GO
AVITA Medical (RCEL) announced the presentation of new clinical data highlighting the first documented use of RECELL GO in the United Kingdom at the 2026 British Burn Association (BBA) Annual…
AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting
First U.K. case series demonstrates successful use of RECELL GO® in 17 burn and reconstructive surgery patients Findings presented at the British Burn Association Annual Meeting support the role of RE...
Avita Medical management to meet virtually with Lake Street
Virtual Meeting to be held on June 23 hosted by Lake Street.
AVITA Medical Transcript: Status update
Revenue grew 10% sequentially to $19.3 million in Q1, with guidance reaffirmed at $80–$85 million for the year. Operational headwinds have turned to tailwinds, reimbursement issues are resolved, and international expansion is progressing through strong partnerships. Cash runway is sufficient for break-even, with flexibility for future capital needs.
Avita Medical upgraded to Buy from Hold at Lake Street
Lake Street upgraded Avita Medical (RCEL) to Buy from Hold with a price target of $6, up from $3.50. Q1 was Avita’s highest revenue quarter since mid-2024, which the firm…
Avita Medical reports Q1 EPS (35c), consensus (38c)
Reports Q1 revenue $19.3M, consensus $24.65M. Cary Vance, CEO, commented: “Since November, we’ve stabilized the business, improved how we operate, and delivered a solid start to 2026. With sequential ...
Avita Medical reiterates FY26 revenue guidance of $80M-$85M, consensus $116.97M
FY26 revenue is expected to be in the range of $80M-$85M, representing growth of approximately 12%-19% compared to FY25 revenue.
AVITA Medical Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 4% year-over-year and 10% sequentially, driven by RECELL and Cohealyx adoption, with gross margin at 81.7% and operating expenses down 11%. Full-year guidance of $80–$85 million was reaffirmed, and cash use is expected to decrease in Q2.
AVITA Medical Earnings release: Q1 2026
AVITA Medical released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
AVITA Medical Quarterly report: Q1 2026
AVITA Medical has published its Q1 2026 quarterly earnings report on May 14, 2026.
AVITA Medical Slides: Q1 2026
AVITA Medical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 14, 2026.